
Overview
Background
Associate Professor Paul Griffin is the Director of Infectious Diseases at Mater Health Services in Brisbane and Associate Professor of Medicine at the University of Queensland Medical School. He has fellowships in Infectious Diseases from the Royal Australasian College of Physicians, in Clinical Microbiology from the Royal College of Pathologists of Australasia and from the Australasian College of Tropical Medicine.
Paul is the Principal Investigator and Medical Director at Nucleus Network, a specialized contract research organisation specializing in early and late phase trials in infectious diseases where he has been the principal investigator on in excess of 125 clinical trials, predominantly in Infectious Diseases including novel vaccines and Malaria human challenge studies. This includes 8 vaccines for COVID-19 and a number of COVID-19 therapies.
As a Clinical Microbiologist, he maintains an active interest in diagnostic microbiology with a focus on clinical applications of faecal microbiome metagenomic sequencing.
In addition to a teaching role at the University of Queensland, Paul is also the chair of the Advanced Training Committee in Infectious Diseases with the Royal Australasian College of Physicians, the committee that oversees the training of Infectious Diseases specialists in Australia.
Finally, as a director and scientific advisory board member of the immunisation coalition, Paul has an active interest in vaccine education and advocacy and has become a trusted media authority and spokesperson across the nation during the COVID-19 pandemic.
Availability
- Professor Paul Griffin is:
- Available for supervision
- Media expert
Fields of research
Research impacts
While performing vital clinical and research duties, he has also devoted time to inform, educate and reassure the community via a wide range of media appearances. He has featured regularly on prominent Australian programs across television, radio, print and online including The Project, Sunrise, Today Show, A Current Affair, and internationally including Canada’s CTV and the BBC.
Works
Search Professor Paul Griffin’s works on UQ eSpace
2019
Conference Publication
Pharmacokinetic/pharmacodynamic assessment of a proposed biosimilar MSB11455 versus the currently licensed pegfilgrastim: A randomized, double-blind trial
Lickliter, Jason D., Griffin, Paul, Vincent, Emmanuelle, Schuler, Armin, Harrison-Moench, Eleanor, Stahl, Michael, El Bawab, Samer, Kanceva, Radmila and Gascon, Pere (2019). Pharmacokinetic/pharmacodynamic assessment of a proposed biosimilar MSB11455 versus the currently licensed pegfilgrastim: A randomized, double-blind trial. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31May - 4 June, 2019. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2019.37.15_suppl.e14514
2019
Conference Publication
RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration
Collins, Jon, Jones, Lori, Snyder, Michele, Sicard, Eric, Griffin, Paul, Webster, Lindsey, Fong, Regan, Coquery, Christine and Piscitelli, Stephen (2019). RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration. 71st Annual Meeting of the American Academy of Neurology (AAN), Philadelphia, PA, United States, 4-10 May, 2019. Philadelphia, PA, United States: Lippincott Williams & Wilkins.
2019
Conference Publication
RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration
Collins, Jon, Jones, Lori, Snyder, Michele, Sicard, Eric, Griffin, Paul, Webster, Lindsey, Fong, Regan, Coquery, Christine and Piscitelli, Stephen (2019). RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration. AAN 71st Annual Meeting, Philadelphia, PA United States, 4-10 May 2019. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.92.15_supplement.p5.2-079
2019
Journal Article
DSM265 at 400 milligrams clears asexual stage parasites but not mature gametocytes from the blood of healthy subjects experimentally infected with Plasmodium falciparum
Collins, Katharine A., Rueckle, Thomas, Elliott, Suzanne, Marquart, Louise, Ballard, Emma, Chalon, Stephan, Griffin, Paul, Moehrle, Joern J. and McCarthy, James S. (2019). DSM265 at 400 milligrams clears asexual stage parasites but not mature gametocytes from the blood of healthy subjects experimentally infected with Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 63 (4) e01837-18. doi: 10.1128/AAC.01837-18
2019
Journal Article
Qualitative study investigating the underlying motivations of healthy participants in phase I clinical trials
Manton, Kerry J., Gauld, Cassandra S., White, Katherine M., Griffin, Paul M. and Elliott, Suzanne L. (2019). Qualitative study investigating the underlying motivations of healthy participants in phase I clinical trials. BMJ Open, 9 (1) e024224, e024224. doi: 10.1136/bmjopen-2018-024224
2018
Journal Article
Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial
Harris, Patrick N. A., Tambyah, Paul A., Lye, David C., Mo, Yin, Lee, Tau H., Yilmaz, Mesut, Alenazi, Thamer H., Arabi, Yaseen, Falcone, Marco, Bassetti, Matteo, Righi, Elda, Rogers, Benjamin A., Kanj, Souha, Bhally, Hasan, Iredell, Jon, Mendelson, Marc, Boyles, Tom H., Looke, David, Miyakis, Spiros, Walls, Genevieve, Al Khamis, Mohammed, Zikri, Ahmed, Crowe, Amy, Ingram, Paul, Daneman, Nick, Griffin, Paul, Athan, Eugene, Lorenc, Penelope, Baker, Peter ... MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN) (2018). Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA, 320 (10), 984-994. doi: 10.1001/jama.2018.12163
2018
Journal Article
Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial
Proietto, Joseph, Malloy, Jaret, Zhuang, Dongliang, Arya, Mark, Cohen, Neale D., de Looze, Ferdinandus J., Gilfillan, Christopher, Griffin, Paul, Hall, Stephen, Nathow, Thomas, Oldfield, Geoffrey S., O'Neal, David N., Roberts, Adam, Stuckey, Bronwyn G. A., Yue, Dennis, Taylor, Kristin and Kim, Dennis (2018). Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial. Diabetologia, 61 (9), 1918-1922. doi: 10.1007/s00125-018-4677-0
2018
Journal Article
Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial
Sekuloski, Silvana, Batzloff, Michael R., Griffin, Paul, Parsonage, William, Elliott, Suzanne, Hartas, Jon, O'Rourke, Peter, Marquart, Louise, Pandey, Manisha, Rubin, Fran A., Carapetis, Jonathan, McCarthy, James and Good, Michael F. (2018). Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial. PLoS One, 13 (7) e0198658, e0198658. doi: 10.1371/journal.pone.0198658
2018
Journal Article
Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™)
Fernando, Germain J. P., Hickling, Julian, Jayashi Flores, Cesar M., Griffin, Paul, Anderson, Christopher D., Skinner, S. Rachel, Davies, Cristyn, Witham, Katey, Pryor, Melinda, Bodle, Jesse, Rockman, Steve, Frazer, Ian H. and Forster, Angus H. (2018). Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™). Vaccine, 36 (26), 3779-3788. doi: 10.1016/j.vaccine.2018.05.053
2018
Journal Article
The Dynamics of Liver Function Test Abnormalities after Malaria Infection: A Retrospective Observational Study
Woodford, John, Shanks, G Dennis, Griffin, Paul, Chalon, Stephan and McCarthy, James (2018). The Dynamics of Liver Function Test Abnormalities after Malaria Infection: A Retrospective Observational Study. The American Journal of Tropical Medicine and Hygiene, 98 (4), 1113-1119. doi: 10.4269/ajtmh.17-0754
2018
Conference Publication
A fitst-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and fluorescence contrast in skin cancer
Yamada, M., Miller, D., Lowe, M., Rowe, C., Wood, D., Byrnes-Blake, K., Parrish-Novak, J., Ishak, L., Olson, J., Brandt, G., Griffin, P., Spleman, L. and Prow, T. (2018). A fitst-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and fluorescence contrast in skin cancer. International Investigative Dermatology (IID) Meeting, Orlando, FL, United States, 16-19 May 2018. New York, United States: Elsevier.
2017
Journal Article
Safety, acceptability and tolerability of uncoated and excipient-coated high density silicon micro-projection array patches in human subjects
Griffin, Paul, Elliot, Suzanne, Krauer, Kenia, Davies, Cristyn, Skinner, Rachel, Anderson, Christopher D. and Forster, Anguis (2017). Safety, acceptability and tolerability of uncoated and excipient-coated high density silicon micro-projection array patches in human subjects. Vaccine, 35 (48), 6676-6684. doi: 10.1016/j.vaccine.2017.10.021
2017
Journal Article
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study
McCarthy, James S., Lotharius, Julie, Ruckle, Thomas, Chalon, Stephan, Phillips, Margaret A., Elliott, Suzanne, Sekuloski, Silvana, Griffin, Paul, Ng, Caroline L., Fidock, David A., Marquart, Louise, Williams, Noelle S., Gobeau, Nathalie, Bebrevska, Lidiya, Rosario, Maria, Marsh, Kennan and Mohrle, Jorg J. (2017). Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. The Lancet Infectious Diseases, 17 (6), 626-635. doi: 10.1016/S1473-3099(17)30171-8
2017
Journal Article
First Australian case of disseminated Mycobacterium chimaera infection post-cardiothoracic surgery
Bursle, Evan, Playford, E. Geoffrey, Coulter, Chris and Griffin, Paul (2017). First Australian case of disseminated Mycobacterium chimaera infection post-cardiothoracic surgery. Infection, Disease and Health, 22 (1), 1-5. doi: 10.1016/j.idh.2017.01.003
2017
Book Chapter
Furazolidone (furazolidine)
Doshi, Jaslyn and Griffin, Paul M. (2017). Furazolidone (furazolidine). Kucers’ the use of antibiotics: A clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs. (pp. 3187-3194) edited by M. Lindsay Grayson, Sara E. Cosgrove, Suzanne Crowe, William Hope, James S. McCarthy, John Mills, Johan W. Mouton and David L. Paterson. Boca Raton, FL United States: CRC Press. doi: 10.1201/9781315152110
2017
Book Chapter
Diloxanide furoate
Eisemann, Jared E. and Griffin, Paul M. (2017). Diloxanide furoate. Kucers’ the use of antibiotics: A clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs. (pp. 3195-3199) edited by M. Lindsay Grayson, Sara E. Cosgrove, Suzanne Crowe, William Hope, James S. McCarthy, John Mills, Johan W. Mouton and David L. Paterson. Boca Raton, FL United States: CRC Press. doi: 10.1201/9781315152110
2017
Journal Article
MALDI-TOF MS meets WGS in a VRE outbreak investigation
Schlebusch, S., Price, G. R., Gallagher, R. L., Horton-Szar, V., Elbourne, L. D. H., Griffin, P., Venter, D. J., Jensen, S. O. and van Hal, S. J. (2017). MALDI-TOF MS meets WGS in a VRE outbreak investigation. European Journal of Clinical Microbiology and Infectious Diseases, 36 (3), 1-5. doi: 10.1007/s10096-016-2824-4
2017
Book Chapter
Niclosamide
Griffin, Paul M. and McCarthy, James (2017). Niclosamide. Kucers’ the use of antibiotics: A clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs. (pp. 3405-3409) edited by M. Lindsay Grayson, Sara E. Cosgrove, Suzanne Crowe, William Hope, James S. McCarthy, John Mills, Johan W. Mouton and David L. Paterson. Boca Raton, FL United States: CRC Press. doi: 10.1201/9781315152110
2016
Journal Article
Plasmodium vivax controlled human malaria infection - progress and prospects
Payne, Ruth O., Griffin, Paul M., McCarthy, James S. and Draper, Simon J. (2016). Plasmodium vivax controlled human malaria infection - progress and prospects. Trends in Parasitology, 33 (2), 141-150. doi: 10.1016/j.pt.2016.11.001
2016
Journal Article
Safety and reproducibility of a clinical trial system using induced blood stage Plasmodium vivax infection and its potential as a model to evaluate malaria transmission
Griffin, Paul, Pasay, Cielo, Elliott, Suzanne, Sekuloski, Silvana, Sikulu, Maggy, Hugo, Leon, Khoury, David, Cromer, Deborah, Davenport, Miles, Sattabongkot, Jetsumon, Ivinson, Karen, Ockenhouse, Christian and McCarthy, James (2016). Safety and reproducibility of a clinical trial system using induced blood stage Plasmodium vivax infection and its potential as a model to evaluate malaria transmission. PLoS Neglected Tropical Diseases, 10 (12) e0005139, e0005139. doi: 10.1371/journal.pntd.0005139
Funding
Past funding
Supervision
Availability
- Professor Paul Griffin is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Media
Enquiries
Contact Professor Paul Griffin directly for media enquiries about:
- COVID-19
- Infectious Diseases
- microbiology
- Vaccines
Need help?
For help with finding experts, story ideas and media enquiries, contact our Media team: